share_log

Wells Fargo Maintains Overweight on Blueprint Medicines, Lowers Price Target to $151

Benzinga ·  Nov 1 03:46  · Ratings

Wells Fargo analyst Derek Archila maintains Blueprint Medicines (NASDAQ:BPMC) with a Overweight and lowers the price target from $153 to $151.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment